I'll Mike. walking Thank be Scott can our the by website our in as through which, commercial found X-K on today. issued you, start metrics, mentioned, we
provide X, of ZILRETTA's several that Slide on with context the which launch. includes progress begin key metrics I'll important
of mentioned, the in our target of Mike quarter, over XX% we X,XXX the of net growth $XX.X million nearly second representing all third As recorded we called sales accounts. and quarter,
introduced have ZILRETTA, enhancements as continued such organization; we and to factors, volume-based strong positive taken program adoption the health provider rebate third code sales steps key our believe, considerations the of number in we and to Our with growth, the quarter-over-quarter associated is to economic of care very attributable commercial the quarter. including: J we physician permanent address feedback; and a patient Ongoing
target of number broaden the expect as we calls, sales reach. to previous on our their reps discussed we've As accounts grow
accounts had third accounts the of ZILRETTA, end to an of purchased which XXX product quarter. accounts end is the purchasing purchased second the increase of that compared the had as of At the X,XXX X,XXX quarter, approximately
to With quarters. last we reorder rate respect over have the X seen tick up reorders, our
purchasing X of September is XX% as accounts X,XXX least second growing and of off at of reorder respectively. reorder the end accounts the and increase of base. a customer placed XX% XX%, first the As this ZILRETTA. were quarters, And or for rates XX, And had of we
Moving to X. Slide
ZILRETTA's XXXX clear we our the the million to Mike year earlier, confidence market. see in third This growth the of in full a graph this a $XX $XX.X our very sales quarterly tighten to quarter. in guidance And us net since stated of picture Here, the provides you $XX as million to sales million. with range paints can launch, sales including net recorded
purchasing Now practices, sizes hospitals of two reflect on accounts, ZILRETTA physician clinics Slide and the which slides slide various by potential. of and and X; this purchases remaining represent
purchased distribution we the XX quarter, we XX XX more with units. accounts purchased in we to As groupings the units purchased at shared or since that launch, to stayed that same than X that look accounts have XX purchased have the units, of ZILRETTA second
number made roughly significant continue purchases in XX this see units. accounts a X X,XXX XX, had September accounts We of to as with purchases of And range. to of
customer I growing and patient purchases range new ZILRETTA to the of as on with in accounts the frequency feedback As experienced mentioned orders they this receive place expand of generally consistent we continued often reliable before, time their the and benefits and reimbursement. and have initial size base over
XX purchased XXX had the to As than end XX third more of quarter, of units. accounts the
In the than accounts had purchased over June XX, more period XX units, XX% representing through from addition, launch XXX XXXX. growth
be with progress. this to continue pleased We very
meaningful these whom incorporate ZILRETTA still fully adopters, practices. highest consider to more early their accounts we for However, there's utilizing opportunity into
to see early-adopting of the date. purchases accounts these on to Slide X; significance the ZILRETTA can total Moving of you clearly
purchases all more that XXX,XXX total units than purchasing of XX% the XX% about of since is accounts, units XX the which purchased launch. accounts While or have roughly XXX, number of approximately total accounts purchased is these
accounts X we previously, accounts. continuum to As units units, ZILRETTA and which then to XX more XX the current base X,XXX XX from from utilization for along have approximately units mentioned the generally potential highlights significant our purchasing than sales to XX move customer of to
breaks accounts. Looking existing at the how by Slide X; can and ZILRETTA out you see new purchasing
previously, over confidence mentioned addition while slowing of new see the board continued accounts the in potential. I us expect tremendous coming long-term quarter, As new we of number to in time ZILRETTA's each a on gives accounts
third quarter was our So, for compared XXXX the sales million $XX.X the share loss third the XXXX, through period was quarter reported The of net sales press sales cost and the of loss quarter the million a respectively. $X million net and of third the net which in per quarter of this to or third $XX.X $X.XX for $X.X $X of in of ZILRETTA the briefly of of same to million of per release million now for XX-Q. million The let or for net me and $X.X issued we XXXX. of results, compared XXXX. walk share financial for third XXXX quarter afternoon XXXX included $XX.X We
of Medicaid, Defense. and net The and care gross-to-net of reflect service The fees, comprised Veterans rebates, XX%. distributor third health quarter returns as mandatory rebates XXXB XXXX reserve, and Department primarily institutions discounts and gross-to-net Administration and the of sales reduction government provider is such reduction
product in gross-to-net of previously started provider we of mentioned, third of volume third the These quarter we variable X% health purchase. on care providers the As total that contributed offering XX%. rebates to quarter, reduction rebates are eligible based the
expenses ended $XX.X development research and months of X and were Research The a development million $XX.X primarily and XXXX, increase XXXX million the was respectively. for due to million in September XX, and $X.X expenses life-cycle to XENXXX costs million and payment management related Xenon expenses for $X activities. the shoulder to for rights trial clinical million increased upfront Pharmaceuticals for global ZILRETTA and hip to other and development $X.X
were million million the respectively. and XX, administrative X the and and months XXXX expenses General XXXX million. and expenses XXXX, million $XX.X XXXX, XXXX $XX.X XX, $X.X XX, X September respectively, $X.X $X.X $XX.X September the for ended and general and million a were administrative ended months represents were expenses which and respectively. and Selling September million XXXX, decrease Selling, $XX.X ended for million X months for of
ended X respectively. expense income million million Interest was $X.X XXXX, Interest and million and September $X.X XX, million months and XXXX was ended September months XXXX for X $X.X and the for the XX, $X.X XXXX.
increase activities ZILRETTA, that activities operating line of continued the development with associated in trials primarily and ZILRETTA, our and expect extension, commercial to driven support We additions future pipeline. by will for expenses continue FXXXX to development FXXXX clinical of
and securities we $XXX.X in XX, cash expenses, We XXXX. balance, bring to with our XXXX, XX, future believe compared cash, sales profitability. that December equivalents marketable with expected of ZILRETTA ongoing as cash had of and approximately our prudent the As will of the of current management million million $XXX.X September us
With that, the decisions, funding potential best as what shareholders. and we long-term do we that it relates we be add is to opportunistic Flexion it said, interest believe as will our of to in always, in important will is
At ask line open questions. for this the operator, point, I please would the
